Ensuring Safe Access to Mifepristone During the Pandemic and Beyond.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 33085508.
- Also identified by DOI 10.7326/M20-6671 and PMC identifier 7592805.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This article discusses the risk evaluation and mitigation strategy (REMS) program imposed by the Food and Drug Administration for mifepristone.
Medical subject headings
- Abortion, Induced
- COVID-19
- Mifepristone
- Pandemics